A phase 3, randomized, open-label study evaluating the safety and efficacy of magrolimab in combination with azacitidine in previously untreated patients with TP53-mutant acute myeloid leukemia
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Conference item |
| Language: | English |
| Published: |
Wiley
2022
|
| _version_ | 1826308860531441664 |
|---|---|
| author | Daver, N Vyas, P Chao, MP Xing, G Renard, C Ramsingh, G Sallman, DA Wei, AH |
| author_facet | Daver, N Vyas, P Chao, MP Xing, G Renard, C Ramsingh, G Sallman, DA Wei, AH |
| author_sort | Daver, N |
| collection | OXFORD |
| description | |
| first_indexed | 2024-03-07T07:25:36Z |
| format | Conference item |
| id | oxford-uuid:516b0853-2c82-4aae-a540-4b4230015c58 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T07:25:36Z |
| publishDate | 2022 |
| publisher | Wiley |
| record_format | dspace |
| spelling | oxford-uuid:516b0853-2c82-4aae-a540-4b4230015c582022-11-17T10:46:05ZA phase 3, randomized, open-label study evaluating the safety and efficacy of magrolimab in combination with azacitidine in previously untreated patients with TP53-mutant acute myeloid leukemiaConference itemhttp://purl.org/coar/resource_type/c_c94fuuid:516b0853-2c82-4aae-a540-4b4230015c58EnglishSymplectic ElementsWiley2022Daver, NVyas, PChao, MPXing, GRenard, CRamsingh, GSallman, DAWei, AH |
| spellingShingle | Daver, N Vyas, P Chao, MP Xing, G Renard, C Ramsingh, G Sallman, DA Wei, AH A phase 3, randomized, open-label study evaluating the safety and efficacy of magrolimab in combination with azacitidine in previously untreated patients with TP53-mutant acute myeloid leukemia |
| title | A phase 3, randomized, open-label study evaluating the safety and efficacy of magrolimab in combination with azacitidine in previously untreated patients with TP53-mutant acute myeloid leukemia |
| title_full | A phase 3, randomized, open-label study evaluating the safety and efficacy of magrolimab in combination with azacitidine in previously untreated patients with TP53-mutant acute myeloid leukemia |
| title_fullStr | A phase 3, randomized, open-label study evaluating the safety and efficacy of magrolimab in combination with azacitidine in previously untreated patients with TP53-mutant acute myeloid leukemia |
| title_full_unstemmed | A phase 3, randomized, open-label study evaluating the safety and efficacy of magrolimab in combination with azacitidine in previously untreated patients with TP53-mutant acute myeloid leukemia |
| title_short | A phase 3, randomized, open-label study evaluating the safety and efficacy of magrolimab in combination with azacitidine in previously untreated patients with TP53-mutant acute myeloid leukemia |
| title_sort | phase 3 randomized open label study evaluating the safety and efficacy of magrolimab in combination with azacitidine in previously untreated patients with tp53 mutant acute myeloid leukemia |
| work_keys_str_mv | AT davern aphase3randomizedopenlabelstudyevaluatingthesafetyandefficacyofmagrolimabincombinationwithazacitidineinpreviouslyuntreatedpatientswithtp53mutantacutemyeloidleukemia AT vyasp aphase3randomizedopenlabelstudyevaluatingthesafetyandefficacyofmagrolimabincombinationwithazacitidineinpreviouslyuntreatedpatientswithtp53mutantacutemyeloidleukemia AT chaomp aphase3randomizedopenlabelstudyevaluatingthesafetyandefficacyofmagrolimabincombinationwithazacitidineinpreviouslyuntreatedpatientswithtp53mutantacutemyeloidleukemia AT xingg aphase3randomizedopenlabelstudyevaluatingthesafetyandefficacyofmagrolimabincombinationwithazacitidineinpreviouslyuntreatedpatientswithtp53mutantacutemyeloidleukemia AT renardc aphase3randomizedopenlabelstudyevaluatingthesafetyandefficacyofmagrolimabincombinationwithazacitidineinpreviouslyuntreatedpatientswithtp53mutantacutemyeloidleukemia AT ramsinghg aphase3randomizedopenlabelstudyevaluatingthesafetyandefficacyofmagrolimabincombinationwithazacitidineinpreviouslyuntreatedpatientswithtp53mutantacutemyeloidleukemia AT sallmanda aphase3randomizedopenlabelstudyevaluatingthesafetyandefficacyofmagrolimabincombinationwithazacitidineinpreviouslyuntreatedpatientswithtp53mutantacutemyeloidleukemia AT weiah aphase3randomizedopenlabelstudyevaluatingthesafetyandefficacyofmagrolimabincombinationwithazacitidineinpreviouslyuntreatedpatientswithtp53mutantacutemyeloidleukemia AT davern phase3randomizedopenlabelstudyevaluatingthesafetyandefficacyofmagrolimabincombinationwithazacitidineinpreviouslyuntreatedpatientswithtp53mutantacutemyeloidleukemia AT vyasp phase3randomizedopenlabelstudyevaluatingthesafetyandefficacyofmagrolimabincombinationwithazacitidineinpreviouslyuntreatedpatientswithtp53mutantacutemyeloidleukemia AT chaomp phase3randomizedopenlabelstudyevaluatingthesafetyandefficacyofmagrolimabincombinationwithazacitidineinpreviouslyuntreatedpatientswithtp53mutantacutemyeloidleukemia AT xingg phase3randomizedopenlabelstudyevaluatingthesafetyandefficacyofmagrolimabincombinationwithazacitidineinpreviouslyuntreatedpatientswithtp53mutantacutemyeloidleukemia AT renardc phase3randomizedopenlabelstudyevaluatingthesafetyandefficacyofmagrolimabincombinationwithazacitidineinpreviouslyuntreatedpatientswithtp53mutantacutemyeloidleukemia AT ramsinghg phase3randomizedopenlabelstudyevaluatingthesafetyandefficacyofmagrolimabincombinationwithazacitidineinpreviouslyuntreatedpatientswithtp53mutantacutemyeloidleukemia AT sallmanda phase3randomizedopenlabelstudyevaluatingthesafetyandefficacyofmagrolimabincombinationwithazacitidineinpreviouslyuntreatedpatientswithtp53mutantacutemyeloidleukemia AT weiah phase3randomizedopenlabelstudyevaluatingthesafetyandefficacyofmagrolimabincombinationwithazacitidineinpreviouslyuntreatedpatientswithtp53mutantacutemyeloidleukemia |